Octapharma and Pharmimex to build plant for human factor VIII products in Russia

3 February 2017

Pharmimex, one of Russia’s leading drugmakers, and the Swedish unit of Swiss biotech firm Octapharma, have announced plans to invest up to 6 billion roubles ($102 million) in building of a new manufacturing plant for human cell-line derived recombinant factor VIII products in the Russian region of Ryazan.

According to Alexander Apazov, president of Pharmimex, that will be full-cycle production of drugs such as von Willebrand factor, human factor VIII, stabilized with von Willebrand factor, human factor IX, concentrate immunoglobulin 5%, immunoglobulin 10% and some others.

The beginning of the construction of the plant is scheduled for 2017. The plant will reach its full design capacity in 2022.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK